Can Acupuncture be a Part of the Treatment for Breast Cancer-Related Lymphedema? A Systematic Review of the Safety and Proposed Model for Care.

Pub Date : 2023-11-29 DOI:10.2458/lymph.5873
J. K. Kim, C. Loo, J. S. Kim, C. Pranskevich, O. K. Gordon
{"title":"Can Acupuncture be a Part of the Treatment for Breast Cancer-Related Lymphedema? A Systematic Review of the Safety and Proposed Model for Care.","authors":"J. K. Kim, C. Loo, J. S. Kim, C. Pranskevich, O. K. Gordon","doi":"10.2458/lymph.5873","DOIUrl":null,"url":null,"abstract":"Acupuncture is a potential therapy for breast cancer-related lymphedema (BCRL). Despite a recent meta-analysis on efficacy, data on acupuncture safety in BCRL are lacking. Current clinical guidelines recommend avoiding needling in the upper extremity affected by lymph node dissection. We undertook a systematic review focusing on acupuncture safety and treatment protocols in clinical trials for BCRL. Literature searches were conducted in PubMed, Ovid, CINAHL, and Cochrane library. Eight clinical trials on acupuncture for BCRL were analyzed. The Standards of Acupuncture intervention (STRICTA 2010) and Cochrane risk of bias (RoB2 2019) were applied to assess methods for acupuncture interventions within Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) framework. Quantity and severity of adverse events (AE) were reviewed. A total of 189 subjects participated in 8 clinical trials with 2965 acupuncture treatments. No serious adverse events (SAE) were reported regardless of treatment laterality or protocol, with only a single grade 2 skin infection in 2,965 total treatments (0.034%), including 1,165 bilateral and 225 ipsilateral treatments. Our comprehensive review of clinical trials of acupuncture for BCRL demonstrated no significant adverse events in 2,965 treatments, including 1,390 in the affected limb. An approach for routine integration of acupuncture into BCRL maintenance therapy is proposed.","PeriodicalId":0,"journal":{"name":"","volume":"25 1","pages":"27-39"},"PeriodicalIF":0.0,"publicationDate":"2023-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2458/lymph.5873","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Acupuncture is a potential therapy for breast cancer-related lymphedema (BCRL). Despite a recent meta-analysis on efficacy, data on acupuncture safety in BCRL are lacking. Current clinical guidelines recommend avoiding needling in the upper extremity affected by lymph node dissection. We undertook a systematic review focusing on acupuncture safety and treatment protocols in clinical trials for BCRL. Literature searches were conducted in PubMed, Ovid, CINAHL, and Cochrane library. Eight clinical trials on acupuncture for BCRL were analyzed. The Standards of Acupuncture intervention (STRICTA 2010) and Cochrane risk of bias (RoB2 2019) were applied to assess methods for acupuncture interventions within Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) framework. Quantity and severity of adverse events (AE) were reviewed. A total of 189 subjects participated in 8 clinical trials with 2965 acupuncture treatments. No serious adverse events (SAE) were reported regardless of treatment laterality or protocol, with only a single grade 2 skin infection in 2,965 total treatments (0.034%), including 1,165 bilateral and 225 ipsilateral treatments. Our comprehensive review of clinical trials of acupuncture for BCRL demonstrated no significant adverse events in 2,965 treatments, including 1,390 in the affected limb. An approach for routine integration of acupuncture into BCRL maintenance therapy is proposed.
分享
查看原文
针灸可以作为乳腺癌相关淋巴水肿治疗的一部分吗?安全性系统回顾及护理模式建议。
针灸是治疗乳腺癌相关淋巴水肿(BCRL)的一种潜在疗法。尽管最近有一项关于疗效的荟萃分析,但仍缺乏有关针刺治疗乳腺癌相关淋巴水肿安全性的数据。目前的临床指南建议避免针刺受淋巴结清扫影响的上肢。我们进行了一项系统性综述,重点关注针刺治疗 BCRL 的安全性和临床试验中的治疗方案。我们在 PubMed、Ovid、CINAHL 和 Cochrane 图书馆进行了文献检索。对八项针灸治疗 BCRL 的临床试验进行了分析。针灸干预标准(STRICTA 2010)和Cochrane偏倚风险(RoB2 2019)被应用于系统综述和荟萃分析首选报告项目(PRISMA)框架内的针灸干预评估方法。对不良事件(AE)的数量和严重程度进行了审查。共有 189 名受试者参加了 8 项临床试验,接受了 2965 次针灸治疗。在总计 2965 次治疗(0.034%)中,包括 1165 次双侧治疗和 225 次同侧治疗,无严重不良事件(SAE)报告,仅有一次 2 级皮肤感染(0.034%)。我们对针灸治疗 BCRL 的临床试验进行了全面回顾,结果表明在 2,965 次治疗中,包括 1,390 次患肢治疗,未出现明显的不良事件。我们提出了将针灸纳入 BCRL 维持治疗的常规方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信